ISR Holding: Nigel Goodman Chief of Clinical operations presents at Redeye Initiate September 1st, 2022

ISR Rapport för det första halvåret 2022

ISR har nu stängt inklusionen till HIV studien ISR-003

Nytt datum för Halvårsrapport 2022

SARS-CoV-2 vaccine study approved by Bangladesh BMRC

Uppdatering kring styrelsens sammansättning i ISR

ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.

ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.

Redeye - Get to know Ola Winqvist

Delegation from Bangladesh visits ISR for study preparation